

## 2025 ASTCT Fundamentals of HCT Virtual Training Course

April 3, 2025 - April 4, 2025

### TARGET AUDIENCE

The target audience for this activity includes physicians, pharmacists, and nurses including new practitioners, residents, fellows, and all other health care providers training in this discipline.

### PROGRAM OVERVIEW

The Fundamentals of HCT Training Course is a 2-day conference that provides a broad overview and introduction of hematopoietic cell transplantation (HCT), also referred to as blood and marrow transplantation (BMT), as well as cellular immunotherapy (CI). Throughout the lectures, participants will be introduced to numerous aspects of the HCT-CI processes, which are designed to develop or enhance skills required in the management of patients undergoing these procedures. This course incorporates case-based learning to emphasize application of concepts taught through didactic lecture with a strong focus on the pharmacotherapeutic management.

The Fundamentals of HCT Training Course is designed to inform attendees about the latest developments in 1) treatment guidelines; 2) therapeutic regimens; 3) diseases state management; 4) supportive care therapies; 5) controversial care issues; and 6) clinical trial data.

### LEARNING OBJECTIVES

- Discuss current clinical practice and challenges for healthcare professionals in the field of hematopoietic cell transplantation (HCT) and cellular immunotherapy
- Identify best practice strategies and clinical challenges related to introduction to transplant, donor selection and HLA typing, stem cell mobilization, conditioning, immune effector cell therapy and toxicity management, peri-transplant complications, pulmonary complications, sinusoidal obstruction syndrome, viral infections, fungal infections, acute graft versus host disease, chronic graft versus host disease, thrombotic microangiopathy, geriatrics, pediatrics, maintenance strategies, and survivorship
- Examine patient case studies related to introduction to transplant, donor selection and HLA typing, stem cell mobilization, conditioning, immune effector cell therapy and toxicity management, peri-transplant complications, pulmonary complications, sinusoidal obstruction syndrome, viral infections, fungal infections, acute graft versus host disease, chronic graft versus host disease, thrombotic microangiopathy, geriatrics, pediatrics, maintenance strategies, and survivorship

### INSTRUCTIONS FOR PARTICIPATION AND REQUESTING CREDIT

There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the activity, and completing the evaluation form.

### Credit Fulfillment

- If you are requesting AMA credits, ANCC credits, or a certificate of participation, your certificate will be available for download.
- If you are a pharmacist requesting ACPE credits, your credit request will be uploaded to CPE Monitor within 60 days after the activity.

**Note:** There is ONE evaluation for the entire program, not one for each individual session. A link for the CE evaluation will be provided post-conference.

Technical Requirements: <http://www.francefoundation.com/general-requirements.html>

## **ACCREDITED PROVIDER**

This activity is jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT).



## **Accreditation Statement**



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

## **PHYSICIAN CREDIT DESIGNATION**



The France Foundation designates this live activity for a maximum of 14.5 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **NURSES**



The France Foundation designates this activity for 14.5 contact hours.

## **PHARMACISTS**



This knowledge and application-based activity qualifies for 14.5 contact hours (0.145 CEUs) of continuing pharmacy education credit. **Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date.** Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service ([custserv@nabp.net](mailto:custserv@nabp.net)).

All other health care professionals completing this course will be issued a statement of participation.

## Program Agenda

Thursday, 4/3/2025 (CST)	Topic		Hours (CEUs)	UAN #s	
8:00 – 8:10 AM	<b>Welcome &amp; Opening Remarks</b> Kendall Schultes, PharmD, BCOP; VA Tennessee Valley Healthcare System, Nashville, TN				
8:10 – 8:40 AM	<b>Introduction to Hematopoietic Cell Transplantation</b> Jason Ernstberger, PharmD, BCOP; University of Cincinnati Medical Center, Cincinnati, OH		0.5 (0.05)	JA0007204-9999-25-036-L01-P	
8:45 – 9:30 AM	<b>Donor Selection and Introduction to HLA Typing</b> Marco Ruiz, MD; Baptist Health Miami Cancer Institute, Miami, FL		0.75 (0.075)	JA0007204-9999-25-037-L01-P	
9:35 – 10:05 AM	<b>Hematopoietic Stem Cell Mobilization</b> Erika Wass, PharmD, BCOP; Loma Linda University Medical Center, Loma Linda, CA		0.5 (0.05)	JA0007204-9999-25-038-L01-P	
10:05 – 10:15 AM (10)	<b>BREAK</b>				
10:15 – 11:15 AM	<b>Principles of Conditioning in Hematopoietic Cell Transplantation</b> Binni Kunvarjee, PharmD, BCOP; Memorial Sloan Kettering Cancer Center, New York, NY		1.0 (0.1)	JA0007204-9999-25-039-L01-P	
11:20 – 12:20 PM	<b>Supportive Care for Peri-Transplant Complications</b> Amber Clemmons, PharmD, BCOP; University of Georgia, Augusta, GA		1.0 (0.1)	JA0007204-9999-25-040-L01-P	
12:20 – 12:40 PM (30)	<b>LUNCH</b>				
12:40 – 1:25 PM	<b>Thrombotic Microangiopathy in HCT</b> Hemalatha Rangarajan, MD; Nationwide Children's Hospital, Columbus, OH	<b>Pulmonary Complications of HCT</b> Samuel Goldfarb, MD; University of Minnesota, Minneapolis, MN	0.75 (0.075)	JA0007204-9999-25-041-L01-P	JA0007204-9999-25-042-L01-P
1:30 – 2:15 PM	<b>Veno Occlusive Disease/ Sinusoidal Obstructive Syndrome</b> Teresa Rushing, PharmD, BCOP; Children's Hospital Los Angeles, Los Angeles, CA		0.75 (0.075)	JA0007204-9999-25-043-L01-P	
2:15 – 2:25 PM (10)	<b>BREAK</b>				
2:25 – 3:25 PM	<b>Immune Effector Cell Products and Indications</b> Jennifer Collins, PharmD, BCOP; University of Chicago Medicine, Chicago, IL		1.0 (0.1)	JA0007204-9999-25-044-L01-P	

3:30 – 4:30 PM	<b>Immune Effector Cell Management of Toxicities and Complications</b> Cameron Ninos, PharmD, BCOP; University of Wisconsin – Madison, Madison, WI		1.0 (0.1)	JA0007204-9999-25-052-L01-P	
4:30 – 5:00 PM	<b>Virtual Roundtable Discussion &amp; Wrap-Up (*No CE provided)</b>				
	<b>Day 1 Concludes</b>		<b>7.25 (0.725)</b>		
<b>Friday, 4/4/2025 (CST)</b>	<b>Topic</b>		<b>Hours (CEUs)</b>	<b>UAN #s</b>	
8:00 – 9:00 AM	<b>Fungal Infections in Hematopoietic Cell Transplantation</b> Arpita Gandhi, PharmD, BCOP; Emory Healthcare - Winship Cancer Institute, Atlanta, GA		1.0 (0.1)	JA0007204-9999-25-045-L01-P	
9:05 – 10:05 AM	<b>Viral Infections in Hematopoietic Cell Transplantation</b> LeAnne Kennedy, PharmD, BCOP; Atrium Health Wake Forest Baptist, Winston-Salem, NC		1.0 (0.1)	JA0007204-9999-25-046-L01-P	
10:05 – 10:15 AM (10)	<b>BREAK</b>				
10:15 – 11:15 AM	<b>Special Populations in Hematopoietic Cell Transplantation HCT: Pediatrics</b> Susie Long, PharmD; University of Minnesota, Minneapolis, MN	<b>Special Populations in Hematopoietic Cell Transplantation: Geriatrics</b> Andrew Artz, MD; City of Hope, Los Angeles, CA	1.0 (0.1)	JA0007204-9999-25-047-L01-P	JA0007204-9999-25-048-L01-P
11:15 – 11:25 AM (10)	<b>BREAK</b>				
11:25 – 12:40 PM	<b>Acute Graft versus Host Disease</b> Elizabeth DiMaggio, PharmD, BCOP; Moffitt Cancer Center, Tampa, FL		1.25 (0.125)	JA0007204-9999-25-049-L01-P	
12:40 – 1:00 PM (20)	<b>LUNCH</b>				
1:00 – 2:15 PM	<b>Chronic Graft vs Host Disease</b> Rebecca Gonzalez, PharmD, BCOP; Moffitt Cancer Center, Tampa, FL		1.25 (0.125)	JA0007204-9999-25-050-L01-P	
2:15 – 2:25 PM (10)	<b>BREAK</b>				
2:25 – 3:10 PM	<b>Maintenance Strategies after Hematopoietic Cell Transplantation</b> Mary McGann, PharmD, BCOP; MUSC Hollings Cancer Center, Charleston, SC		0.75 (0.075)	JA0007204-9999-25-051-L01-P	
3:15 – 4:15 PM	<b>Long Term Complications and Survivorship in Hematopoietic Cell Transplantation</b> Ila Saunders, PharmD, BCOP; UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA		1.0 (0.1)	JA0007204-9999-25-052-L01-P	

4:15 – 4:45 PM	Virtual Roundtable Discussion & Wrap-Up (*No CE provided)		
	Day 2 Concludes	7.25 (0.725)	

#### DISCLOSURE POLICY

The France Foundation (TFF) and The American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.

Disclosures for members of the planning committee and faculty will be disclosed to learners prior to the conference and can also be found [here](#).

#### Disclosure of Unlabeled Use:

The France Foundation (TFF) and The American Society for Transplantation and Cellular Therapy (ASTCT) require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational. They must also disclose limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

#### Disclaimer:

The France Foundation and the American Society for Transplantation and Cellular Therapy present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, The American Society for Transplantation and Cellular Therapy, and the commercial supporter(s) assume no liability for the information herein.

#### CONTACT INFORMATION

If you have questions about this CME/CE activity, please contact The France Foundation at 860-434-1650 or [info@francefoundation.com](mailto:info@francefoundation.com).